WST · Q4 2025 Earnings

Bullish

West Pharmaceutical Services

Reported February 12, 2026

30-second summary

Q4 revenue of $805M (+7.5% YoY) beat the high end of the prior $790–800M guide and adjusted EPS of $2.04 crushed the $1.81–1.86 guide by $0.18, capping FY2025 at $3.074B / $7.29 — both above the raised Q3 ranges. The FY2026 guide of $3.215–3.275B (5–7% organic, 7.7–12.5% EPS growth) confirms reacceleration from FY2025's 6.3% reported / 4.3% organic (which itself beat the raised 3.75–4.0% organic guide), with management explicitly framing the 10% GLP-1 growth assumption as "very conservative" and HVP Components driving four of five points of total growth. The SmartDose 3.5mL sale to AbbVie (mid-2026 close assumed) cleanly divests the troubled delivery-device asset and refocuses the device portfolio on the elastomer-adjacent WestSynchrony pre-fillable syringe.

Headline numbers

EPS

Q4 FY2025

$2.04

Revenue

Q4 FY2025

$0.81B

+7.5% YoY

Gross margin

Q4 FY2025

37.8%

Operating margin

Q4 FY2025

19.5%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$0.81B	+7.5%	$0.80B	+0.0%
EPS	$2.04	—	$1.96	+4.1%
Gross margin	37.8%	—	36.6%	+120bps
Operating margin	19.5%	—	20.8%	-130bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q4 FY2025	$790 million to $800 million	$805 million	+$5 million above high end of guide	Beat
Adjusted EPS	Q4 FY2025	$1.81 to $1.86	$2.04	+$0.18 above high end of guide	Beat
Revenue	FY2025	$3.060 billion to $3.070 billion	$3.074 billion	+$0.004 billion in-line to slightly above high end	Met
Adjusted EPS	FY2025	$7.06 to $7.11	$7.29	+$0.18 above high end of guide	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	Q1 FY2026	$770 million to $790 million	10.3% to 13.2%
Adjusted EPS	Q1 FY2026	$1.65 to $1.70	13.0% to 16.4%
Revenue	FY2026	$3.215 billion to $3.275 billion	4.6% to 6.5%
Adjusted EPS	FY2026	$7.85 to $8.20	7.7% to 12.5%
Organic Revenue Growth	FY2026	5% to 7%	—
Capital Expenditures	FY2026	$250 million to $275 million	—
Foreign Currency Benefit	FY2026	2 percentage points	—

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
HVP Components	$0.39B	+20.3%
HVP Delivery Devices	$0.11B	-16.9%
Standard Products	$0.162B	+3.0%
Contract-Manufactured Products	$0.143B	+6.2%
Proprietary Products	$0.662B	+7.8%
HVP Components organic growth	15.1%	—
Biologics organic growth	7.3%	—
Pharma organic growth	0.3%	—
Contract Manufacturing organic growth	1.9%	—

Other KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Americas	$0.359B	+1.1%
Europe, Middle East, Africa	$0.37B	+14.6%
Asia Pacific	$0.076B	+7.3%
Operating cash flow	$754.8M	—
Capital expenditures	$285.9M	—
Free cash flow	$468.9M	—
Share repurchases	552,593 shares	—

Management tone

Q3 anchor → Q4 anchor: "Destocking largely behind us" → "Demand outpaces supply globally; non-GLP-1 HVP is the engine."

The growth-driver narrative completed its rotation away from GLP-1 dominance. Heading into 2026, management quantified non-GLP-1 HVP Components as "four of the five points of growth" at the midpoint, with HVP Components overall expected to grow "high single digit to low double digits organically." That is a deliberate reframing: GLP-1 contribution is now a sub-component of HVP, not the story. The point is to demonstrate the business compounds without leaning on a single therapeutic class.

Embedded conservatism in the guide is being telegraphed unusually openly. Asked about the 10% GLP-1 growth assumption appearing soft against recent trends, management said: "What I would characterize that is a very conservative start to our initial guidance. We continue to believe that the adoption is going to be 30%." West's house style is measured, not promotional — explicitly flagging conservatism in an opening FY guide is a notable confidence signal.

The supply narrative shifted from European bottleneck to global structural demand. Q3 framed destocking as behind; Q4 stated: "Demand continues to outpace our supply… we're seeing demand increase significantly frankly, in all HVP plants across the globe, which, as you know, we have five of them." This positions FY2026 capex of $250–275M (below FY2025 actual $285.9M) as a discipline call rather than the absence of opportunity — capacity is being added systematically across all five plants, not crash-built in any one.

Oral GLP-1 risk was reframed from cannibalization to market expansion. Management leaned on third-party data: "Eight of 10 patients using oral GLP-1s are new to the market, suggesting that orals will not cannibalize the injectables market and that several new injectables are about to launch." Citing competitor commentary as validation is a different posture than defending the thesis — management is treating the cannibalization debate as closed.

SmartDose was repositioned from core device opportunity to non-strategic divestiture. SmartDose 3.5mL was previously framed as part of West's on-body delivery growth opportunity; the AbbVie sale (mid-2026 close) reflects management's view that the economics and growth profile do not fit, in contrast to the new WestSynchrony pre-fillable syringe system, which is elastomer-adjacent and aligned with the HVP playbook. The divestiture cleans up the device portfolio narrative that has been the messiest part of the segment disclosure all year.

Recurring themes management leaned on this quarter:

Non-GLP-1 HVP components acceleration as core growth engineAnnex I regulatory compliance driving multi-year $6 billion upgrade opportunityOral GLP-1s expanding market rather than cannibalizing injectablesGlobal capacity expansion required across all five HVP manufacturing plantsMargin expansion 100+ bps from mix shift and utilization improvementWestSynchrony pre-fillable syringe system as new elastomer-adjacent offering

Risks management surfaced:

Tariff landscape could shift from current assumed levelsGLP-1 oral adoption rates could exceed 30% penetration by 2030, reducing injectable demandDemand-supply imbalance could persist longer than expected, constraining revenue growthSmartDose transaction closing delayed beyond mid-year timeframeMulti-dose pen format adoption in U.S. market could accelerate faster than historically anticipated

Answers to last quarter's watch list

Does HVP Delivery Devices stabilize? HVP Delivery Devices printed -16.9% YoY in Q4, with the prior-year incentive fee comp continuing to weigh. The SmartDose divestiture announced this quarter materially changes the segment composition going forward, so the historical comparison loses meaning after the mid-2026 close. Status: Not resolved

Q4 organic growth landing inside the 1.0%–2.3% guide. Q4 organic growth came in at 3.3%, above the guided 1.0%–2.3% band, and FY2025 organic growth of 4.3% beat the high end of the raised 3.75%–4.0% range. The FY raise was not back-loaded into an over-earned Q3. Status: Resolved positively

First quantified FY2026 framing. Delivered in full: revenue $3.215–3.275B (5–7% organic, 4.6–6.5% reported with 2pts FX), EPS $7.85–8.20 (7.7–12.5% growth), capex $250–275M, >100bps operating margin expansion, and explicit framing of HVP Components at high-single-to-low-double-digit organic growth contributing four of five points of total growth. Management also reiterated GLP-1 growth at ~10% as conservative. Status: Resolved positively

Capex stepping toward the 6–8% normal range. FY2026 capex guide of $250–275M on $3.245B midpoint revenue is 7.7%–8.5% — at the top of or marginally above the 6–8% corridor management telegraphed but well below FY2025's actual 9.3% ($285.9M on $3.074B). The directional FCF inflection is intact. Status: Resolved positively

HVP Components sustaining low-mid teens growth in Q4. Resolved emphatically. HVP Components grew +20.3% reported / +15.1% organic in Q4, above the guided "low to mid teens." Annex 1 / HPP upgrade demand is reinforced as structural. Status: Resolved positively

Gross margin holding above 36% with the incentive-fee headwind annualized. Q4 gross margin of 37.8% (+130bps YoY) is the strongest quarterly print of 2025 and clears the threshold convincingly. FY2025 gross margin of 35.9% also exceeds the prior year on a clean basis. Status: Resolved positively

What to watch into next quarter

Q1 FY2026 organic growth landing inside the 4.6%–7.4% guide. A print near the high end would validate management's "very conservative start" framing; below the midpoint would suggest the 10% GLP-1 assumption is more binding than positioned.

HVP Components organic growth holding ≥10% in Q1 to confirm the 2026 trajectory of "four of five points of total growth" is on track from the first quarter, not back-half-weighted.

Operating margin expansion pace through H1. Management guided >100bps for the year "increasing over the course of the year" — watch whether Q1 prints any expansion at all, or whether the entire 100bps is back-loaded.

HVP Delivery Devices ex-SmartDose run-rate. With the SmartDose divestiture pending, watch for the first clean disclosure of the residual delivery-device base so investors can model the segment without the incentive-fee distortion and without SmartDose noise.

GLP-1 dollar disclosure update. Any further refresh of GLP-1 mix would frame the "10% growth = conservative" claim quantitatively.

Tariff impact reconciliation into FY2026. Management has said 2026 fully mitigates the 2025 drag — watch for confirmation in the Q1 print that no incremental tariff hit has emerged from changes in the landscape.

Sources

West Pharmaceutical Services Q4 2025 Earnings Release (SEC EDGAR): https://www.sec.gov/Archives/edgar/data/105770/000010577026000005/exh991q42025earningsrelease.htm
Tapebrief Q3 2025 WST brief (referenced for prior-quarter guidance trajectory and watch list)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.